This article reports what published trial data, FDA labeling, and clinical guidelines describe about blood pressure on testosterone replacement therapy. It is not medical advice. TRT requires a licensed prescriber for individual risk assessment, monitoring, and any dose or medication changes.
The cardiovascular conversation around TRT shifted in 2023 when the TRAVERSE trial showed no excess risk of major adverse cardiac events versus placebo. It shifted again in February 2025 when the FDA, citing TRAVERSE, removed the old cardiovascular boxed warning — but simultaneously added a new class-wide warning that testosterone can raise blood pressure. Both things are true. TRT does not appear to cause heart attacks or strokes in the way the 2014 boxed warning implied, but it does cause a small, real, measurable increase in blood pressure in many men. This page describes what the trial and ambulatory blood pressure data actually show, why the rise happens, who is most susceptible, and how a disciplined TRT clinic monitors and manages it.
If you are weighing TRT and have hypertension, or your blood pressure has crept up since starting therapy, this is the reference page.
What the Trial Data Shows
Three datasets dominate the published evidence base on TRT and blood pressure: the TRAVERSE trial, the FDA-mandated ambulatory blood pressure monitoring (ABPM) studies of individual testosterone products, and a small but mechanistically informative trial in opioid-induced hypogonadism.
TRAVERSE — small but statistically significant SBP rise
TRAVERSE (Lincoff et al., NEJM 2023) randomized 5,246 men aged 45-80 with hypogonadism and pre-existing or high-risk cardiovascular disease to daily transdermal testosterone gel 1.62% or matching placebo. Mean systolic blood pressure changed by +0.3 mm Hg in the testosterone arm versus -1.5 mm Hg in the placebo arm at 6 months (P<0.001 for the between-group difference). The absolute difference is small — roughly 1.8 mm Hg — but it was statistically robust and reproducible across the trial population.
The same trial found no excess risk for the primary cardiovascular endpoint (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), which is what drove the FDA to remove the old boxed warning in 2025. The blood pressure signal is what drove the FDA to add a class-wide BP warning at the same time.
Ambulatory BP studies — about 1.9 mm Hg average 24-hour SBP rise on gel
After a 2018 FDA post-market requirement, manufacturers ran 24-hour ambulatory blood pressure monitoring studies on individual testosterone products. The published gel-1.62% study (Weber et al., Andrology 2025) followed 246 men with low testosterone for 16 weeks. Mean 24-hour systolic blood pressure rose from 123.5 to 125.4 mm Hg — a 1.9 mm Hg increase. That increase technically exceeded the trial's pre-specified non-inferiority threshold, but the authors concluded the clinical relevance of a 1.9 mm Hg mean rise was minimal in light of TRAVERSE's neutral cardiovascular outcomes.
Two important nuances from that study:
- Subgroup performance differed. Non-inferiority was met in subgroups without hypertension or diabetes, but not in subgroups with those conditions. Men with pre-existing cardiometabolic risk factors showed larger, more variable BP responses.
- Class-wide effect. The FDA's February 28, 2025 class-wide labeling change applied to all testosterone products — gels, injectables, oral, transdermal — based on the cumulative ABPM data, not just the gel data.
Hematocrit-mediated BP rise — Olesen et al. 2024
A small, mechanistically informative trial (Olesen et al., Journal of Hypertension, 2024) studied men with opioid-induced androgen deficiency on TRT versus placebo. The testosterone group showed a mean systolic office BP that was 13.2 mm Hg higher than placebo — a much larger effect than TRAVERSE. The trial was in a high-risk subgroup (chronic opioid users, often with obesity), but the key finding was the relationship to hematocrit: a 0.3 percentage-point increase in hematocrit corresponded to roughly a 10 mm Hg increase in systolic blood pressure in their cohort.
This is the most actionable mechanism in the published literature. Polycythemia and blood pressure rise on TRT are not independent problems — they are linked, and managing one often helps the other. See the TRT polycythemia and hematocrit hub for the polycythemia management side.
Why Testosterone Raises Blood Pressure
Several mechanisms have been described in the published literature. Most clinical cases involve more than one acting at once.
Erythrocytosis and viscosity
Testosterone stimulates erythropoiesis. Hematocrit rises in most men starting TRT, and a fraction develop frank polycythemia (hematocrit >54%). Higher red cell mass increases blood viscosity, which raises peripheral vascular resistance and blood pressure. The Olesen trial above quantified this directly. A man whose hematocrit climbs from 45% to 50% on TRT is statistically more likely to also see a 5-10 mm Hg systolic rise — the two move together.
Sodium and fluid retention
Androgens activate renal sodium reabsorption pathways. The fluid-retention effect is small in most men but can be meaningful, particularly in the first 4-8 weeks of therapy when the body is adjusting to a new androgen exposure. This is part of why some men report ankle puffiness, weight gain, or a tighter ring fit early on TRT — and why blood pressure measured at week 6 may already be higher than baseline.
Vascular tone and endothelial effects
Testosterone has direct vascular effects, including changes in nitric oxide signaling and arterial stiffness. The literature is mixed on the net direction — some studies show vasodilation and improved endothelial function, others show stiffening over time. The net clinical effect for BP appears modest but is part of the picture.
Sleep apnea worsening
TRT can worsen obstructive sleep apnea in susceptible men, particularly those who are overweight or who have undiagnosed apnea at baseline. Sleep apnea independently raises blood pressure through sympathetic activation and disrupted nocturnal BP dipping. A man whose BP rises on TRT and who also reports new snoring, daytime fatigue, or a partner-witnessed apnea is a candidate for sleep evaluation. See TRT and sleep apnea for the full discussion.
Weight changes
Body composition shifts on TRT — lean mass up, fat mass typically down — but a meaningful subset of men gain weight in the first 3-6 months from increased appetite, water retention, or expanded red cell mass. Weight gain in this window can independently push blood pressure up regardless of the direct testosterone effect.
Who Is Most Susceptible
The published data and clinic experience converge on a short list of men who are more likely to see a clinically meaningful BP rise on TRT.
| Risk factor | Why it matters |
|---|---|
| Pre-existing hypertension | Smaller BP reserve; ABPM studies showed non-inferiority broke down in this subgroup |
| Diabetes or metabolic syndrome | Already-impaired vascular response; gel ABPM trial showed worse BP outcomes |
| High baseline hematocrit (>48%) | Greater chance of polycythemia, which links directly to BP rise |
| Obstructive sleep apnea | TRT can worsen apnea; apnea worsens BP |
| BMI >30 | Aromatization, sleep apnea risk, and fluid retention all higher |
| Higher TRT dose / supraphysiologic levels | Larger hematocrit and fluid effects scale with dose |
| Once-weekly intramuscular dosing | Larger peak-trough swings; peak periods can drive transient BP rise |
A man with none of these factors and a baseline BP of 118/76 is unlikely to see a clinically meaningful rise on a standard physiologic-dose TRT protocol. A man with a baseline BP of 138/88, hematocrit 49%, BMI 32, and snoring is in a much higher-risk category and warrants closer monitoring.
What Disciplined Clinic Monitoring Looks Like
A clinic that takes blood pressure seriously builds it into the workup rather than waiting for symptoms.
Baseline
- Office blood pressure measurement at the initial consult, with a second confirmatory reading if the first is borderline.
- Hematocrit, hemoglobin, comprehensive metabolic panel, and lipid panel as part of the standard baseline workup.
- Direct question about snoring, witnessed apneas, daytime fatigue, and known sleep apnea diagnosis.
- Documentation of any current antihypertensive medications and their adherence.
- For men with baseline BP >140/90, treating hypertension to target before starting TRT is the conservative approach described in published guidelines.
6-8 week recheck
- Office BP measurement alongside the standard trough total testosterone, free testosterone, estradiol, and CBC.
- A meaningful rise (>5-10 mm Hg systolic) at week 6-8 is a signal to recheck with home or ambulatory monitoring rather than dismissing as noise.
- Hematocrit trend reviewed at the same visit. A hematocrit climb that parallels a BP rise points to the polycythemia-mediated mechanism above.
Ongoing monitoring
- BP and CBC at 3 months, 6 months, then every 6-12 months for stable patients on stable doses.
- Home BP log requested for any patient with borderline or rising readings; isolated office measurements over-call hypertension and miss white-coat effects.
- Annual reassessment of antihypertensive needs as TRT effects on weight, sleep, and hematocrit play out.
The TRT bloodwork schedule describes the broader monitoring cadence; blood pressure fits into that schedule as a vital sign that gets checked at every visit, not a once-a-year afterthought.
What to Do When Blood Pressure Rises
The published literature and clinic experience describe a stepwise workup when BP climbs on TRT.
Step 1: Confirm the rise
A single elevated office reading is not a diagnosis. Home BP monitoring over 1-2 weeks, ideally with a validated upper-arm cuff and morning/evening readings, gives a much more reliable picture. Ambulatory blood pressure monitoring is the reference standard when home readings are equivocal.
Step 2: Check the hematocrit
If the BP has risen meaningfully on TRT, the hematocrit usually has too. The Olesen 2024 mechanism is the most common driver in clinical practice. A hematocrit at or above 52-54% in a man with rising BP points to polycythemia as the proximate cause and reframes the management question.
Step 3: Evaluate the obvious upstream factors
- New or worsened sleep apnea — often the missed driver
- Weight gain, particularly fluid weight in the first 8 weeks
- Sodium load (high-sodium diet, processed food intake)
- New medications (NSAIDs, decongestants, stimulants)
- Alcohol intake changes
Step 4: Consider dose and protocol changes
If hematocrit is climbing and BP with it, the literature describes several levers:
- Lower the testosterone dose to bring trough levels into the lower half of the target range rather than the upper half.
- Switch from once-weekly intramuscular to twice-weekly or every-other-day subcutaneous dosing to smooth the peak-trough curve. Lower peaks generally mean lower hematocrit drift over time. See injection frequency: weekly vs every-other-day and subcutaneous vs intramuscular TRT for the mechanics.
- Therapeutic phlebotomy for confirmed polycythemia (hematocrit >54%), which often produces a BP improvement within weeks.
Step 5: Treat the hypertension if it persists
Most men with sustained, confirmed hypertension on TRT can stay on therapy with the addition of a first-line antihypertensive (ACE inhibitor, ARB, calcium channel blocker, or thiazide depending on the clinical picture). The decision to add or escalate antihypertensives belongs to the prescribing clinician and should be made with the same care as in any patient with hypertension — TRT does not change the antihypertensive treatment algorithm.
Step 6: Discontinue TRT only if BP is uncontrollable
The literature does not support reflexive TRT discontinuation for a 5-10 mm Hg systolic rise. It does support discontinuation for severe, uncontrollable hypertension or for an individual whose risk-benefit picture has shifted. This is a prescriber-level decision, not an internet-forum decision.
How Clinics Vary on This
Not every TRT clinic monitors blood pressure at the standard above. The patterns we have seen across the TRT clinic comparison hub:
- Disciplined clinics: Measure BP at every visit, request home logs when readings drift, manage hematocrit aggressively, do not chase higher peaks just because labs allow it. These clinics earn high marks on the monitoring dimension of the scoring methodology.
- Adequate clinics: Measure BP at baseline and at major rechecks, but rely on patient self-report between visits. Catch most problems but miss some early signal.
- Weak clinics: Do not document baseline BP, do not check it at follow-ups, and only react when a patient reports symptoms. This is the pattern that shows up in TRT clinic red flags.
A clinic that is willing to push your testosterone dose into the upper end of the reference range without monitoring blood pressure or hematocrit is not managing TRT to a clinical standard. The questions to ask a TRT clinic page lists the specific monitoring questions worth asking before signing up.
Common Misreadings
Forum culture and DIY protocols tend to misread the BP question in two directions, both wrong.
- "TRT does not affect blood pressure." It does. The TRAVERSE and ABPM data are clear, and the FDA labeling change in February 2025 reflects that. Pretending the effect is zero is not consistent with the evidence.
- "TRT causes uncontrolled hypertension." It usually does not. The mean effect is a few mm Hg, well within the range that standard antihypertensive management handles. Most men with controlled hypertension can take TRT safely with monitoring. The risk is real but small for most men.
The honest reading is the one in the middle: TRT raises BP a small amount on average, raises it more in susceptible subgroups, and the rise is mostly manageable with good monitoring and standard hypertension treatment when it occurs.
Bottom Line
Testosterone replacement therapy raises systolic blood pressure by roughly 1-2 mm Hg on average in trial populations, with larger and more variable effects in men with pre-existing hypertension, diabetes, or rising hematocrit. The FDA added a class-wide BP warning to all testosterone product labels on February 28, 2025, while simultaneously removing the older cardiovascular boxed warning based on TRAVERSE's neutral primary endpoint. The clinical implication is not "do not start TRT" — it is "monitor blood pressure and hematocrit carefully, treat hypertension to target, and choose a clinic that takes the monitoring seriously." A disciplined TRT clinic builds blood pressure into every visit, manages hematocrit aggressively, and does not push doses past the level your cardiovascular system can handle.